Kymera's IRAK4 Degrader Enters Phase 1 Trial, Triggers $20M Sanofi Milestone — Kymera Therapeutics, Inc.

Event summary

First participant dosed in Phase 1 trial of oral IRAK4 degrader KT-485 (SAR447971) on June 9, 2026.
Trial triggered a $20 million milestone payment from Sanofi under existing collaboration.
Sanofi leads development, regulatory, and commercial efforts for KT-485.
Kymera eligible for up to $975 million in potential milestones related to KT-485.
Phase 1 trial (NCT07629336) evaluates safety, tolerability, and pharmacokinetics in healthy volunteers and HS patients.

The big picture

Kymera's advancement of KT-485 into Phase 1 trials underscores the growing strategic importance of targeted protein degradation in immuno-inflammatory disease treatment. The $20 million milestone payment from Sanofi highlights the financial stakes in this collaboration, while the broader industry shift toward oral small molecule degraders positions Kymera as a key player in this emerging therapeutic class. The success of KT-485 could validate Kymera's platform and attract further partnerships or investment.

What we're watching

Clinical Progress: How the Phase 1 trial results will impact KT-485's development timeline and Sanofi's commitment to the program.
Financial Upside: Whether Kymera can sustain momentum toward the $975 million in potential milestones from the Sanofi collaboration.
Market Positioning: The pace at which Kymera can differentiate KT-485 in the competitive landscape of immuno-inflammatory disease treatments.